Fig. 3From: Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panelProportion of adult patients with NDM who experience a change in QoL over their lifetime. Key: BSC, best supportive careBack to article page